Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,997 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.
Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JL, Levine JE. Uberti JP, et al. Among authors: jones d. Biol Blood Marrow Transplant. 2005 Sep;11(9):680-7. doi: 10.1016/j.bbmt.2005.05.009. Biol Blood Marrow Transplant. 2005. PMID: 16125638 Free article. Clinical Trial.
Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.
Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S. Magenau JM, et al. Among authors: jones dm. Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14. doi: 10.1016/j.bbmt.2010.02.026. Epub 2010 Mar 17. Biol Blood Marrow Transplant. 2010. PMID: 20302964 Free PMC article.
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL. Levine JE, et al. Among authors: jones d. Blood. 2008 Feb 15;111(4):2470-5. doi: 10.1182/blood-2007-09-112987. Epub 2007 Nov 27. Blood. 2008. PMID: 18042798 Free PMC article.
Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.
Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, Krijanovski O, Jones D, Whitfield J, Cooke K, Hutchinson RJ, Ferrara JL, Levine JE. Choi SW, et al. Among authors: jones d. Blood. 2008 Aug 15;112(4):1539-42. doi: 10.1182/blood-2008-02-138867. Epub 2008 May 23. Blood. 2008. PMID: 18502834 Free PMC article.
Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.
Kitko CL, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi SW, Hutchinson RJ, Ferrara JL, Levine JE. Kitko CL, et al. Among authors: jones d. Biol Blood Marrow Transplant. 2008 Jul;14(7):759-65. doi: 10.1016/j.bbmt.2008.04.002. Biol Blood Marrow Transplant. 2008. PMID: 18541194 Free PMC article.
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, Whitfield J, Custer J, Jones D, Ferrara JL, Cooke KR. Yanik GA, et al. Among authors: jones d. Blood. 2008 Oct 15;112(8):3073-81. doi: 10.1182/blood-2008-03-143412. Epub 2008 Jul 29. Blood. 2008. PMID: 18664626 Free PMC article.
A biomarker panel for acute graft-versus-host disease.
Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL. Paczesny S, et al. Among authors: jones d. Blood. 2009 Jan 8;113(2):273-8. doi: 10.1182/blood-2008-07-167098. Epub 2008 Oct 2. Blood. 2009. PMID: 18832652 Free PMC article.
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S. Magenau J, et al. Among authors: jones d. Blood. 2011 Oct 13;118(15):4258-64. doi: 10.1182/blood-2011-06-358010. Epub 2011 Aug 12. Blood. 2011. PMID: 21841163 Free article. Clinical Trial.
14,997 results
You have reached the last available page of results. Please see the User Guide for more information.